Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Echinaforce Hotdrink is a phytopharmaceutical (herbal) formulation developed by A. Vogel Bioforce AG for the treatment of acute uncomplicated influenza. The product is a syrup/hot drink concentrate containing a hydroethanolic extract of freshly harvested *Echinacea purpurea* (comprising 95% herb and 5% root) supplemented with European elderberry (*Sambucus nigra*). It exhibits broad-spectrum antiviral activity against multiple influenza strains, including H1N1, H3N2, and highly pathogenic avian strains (H5N1, H7N7). In a Phase 3 randomized, double-blind, non-inferiority clinical trial, Echinaforce Hotdrink demonstrated comparable efficacy to the neuraminidase inhibitor oseltamivir (Tamiflu) in alleviating flu symptoms, while being associated with a lower incidence of complications and fewer gastrointestinal adverse events such as nausea and vomiting. It is available as an over-the-counter (OTC) medicine in various European markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Echinaforce Hotdrink.